ReconsiDer Tidbits

There was a very interesting article on the topic in the March 28th
edition of the Journal of the American Medical Association (JAMA).
Essentially, what the study showed was that when you compared kids exposed
to cocaine with those who were not exposed, the latter group had better
physical and intellectual development; however, when you compare the
non-exposed children to those exposed to cocaine ONLY, the differences
disappear. In some of these studies, it was the cigarettes and the alcohol
that appeared to be causing the damage, which of course is nothing new.
 
 

Journals of AMA HomeFeedbackSite Map

SubscribeRegisterSearchDocument DeliveryE-Mail AlertClassified
How to use this site
Previous Vol. 285 No. 12,
March 28, 2001

Next
JAMACurrent IssueIndexesPast Issue Index
Review




 
Printable version of this item
 
View Full Text

See Related:
Articles
Authors' Articles


 

 
Return to
Table of Contents

 

 
Author/Article Information
 

to bottom
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to TOP

 
Author/Article Information
 

to bottom
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Growth, Development, and Behavior in Early Childhood Following Prenatal Cocaine Exposure  
 
A Systematic Review 
 
Author Information  Deborah A. Frank, MD; Marilyn Augustyn, MD; Wanda Grant Knight, PhD; Tripler Pell, MSc; Barry Zuckerman, MD

Context  Despite recent studies that failed to show catastrophic effects of prenatal cocaine exposure, popular attitudes and public policies still reflect the belief that cocaine is a uniquely dangerous teratogen.

Objective  To critically review outcomes in early childhood after prenatal cocaine exposure in 5 domains: physical growth; cognition; language skills; motor skills; and behavior, attention, affect, and neurophysiology.

Data Sources  Search of MEDLINE and Psychological Abstracts from 1984 to October 2000.

Study Selection  Studies selected for detailed review (1) were published in a peer-reviewed English-language journal; (2) included a comparison group; (3) recruited samples prospectively in the perinatal period; (4) used masked assessment; and (5) did not include a substantial proportion of subjects exposed in utero to opiates, amphetamines, phencyclidine, or maternal human immunodeficiency virus infection.

Data Extraction  Thirty-six of 74 articles met criteria and were reviewed by 3 authors. Disagreements were resolved by consensus.

Data Synthesis  After controlling for confounders, there was no consistent negative association between prenatal cocaine exposure and physical growth, developmental test scores, or receptive or expressive language. Less optimal motor scores have been found up to age 7 months but not thereafter, and may reflect heavy tobacco exposure. No independent cocaine effects have been shown on standardized parent and teacher reports of child behavior scored by accepted criteria. Experimental paradigms and novel statistical manipulations of standard instruments suggest an association between prenatal cocaine exposure and decreased attentiveness and emotional expressivity, as well as differences on neurophysiologic and attentional/affective findings.

Conclusions  Among children aged 6 years or younger, there is no convincing evidence that prenatal cocaine exposure is associated with developmental toxic effects that are different in severity, scope, or kind from the sequelae of multiple other risk factors. Many findings once thought to be specific effects of in utero cocaine exposure are correlated with other factors, including prenatal exposure to tobacco, marijuana, or alcohol, and the quality of the child's environment. Further replication is required of preliminary neurologic findings.

JAMA. 2001;285:1613-1625

View Full Text    
 
 
Author/Article Information

 
 
Author Affiliations: Boston University School of Medicine (Drs Frank, Augustyn, Grant Knight, and Zuckerman and Ms Pell) and Boston University School of Public Health (Drs Frank and Zuckerman), Boston, Mass.
 
Corresponding Author and Reprints: Deborah A. Frank, MD, Boston Medical Center, Growth and Development Programs, 820 Harrison Ave, FGH Bldg, Third Floor, Boston, MA 02118-2393 (e-mail: dafrank@bu.edu).

Author Contributions: Study concept and design: Frank, Augustyn, Zuckerman.

Acquisition of data: Frank, Augustyn, Pell.

Analysis and interpretation of data: Frank, Augustyn, Grant Knight, Zuckerman.

Drafting of the manuscript: Frank, Grant Knight.

Critical revision of the manuscript for important intellectual content: Augustyn, Pell, Zuckerman.

Obtained funding: Frank.

Administrative, technical, or material support: Augustyn, Grant Knight, Pell, Zuckerman.

Study supervision: Frank, Zuckerman.

Funding/Support: This work was supported by grant DA 06532 from the National Institute of Drug Abuse (Dr Frank).

Acknowledgment: We thank Ruth Rose-Jacobs, ScD, David Bellinger, PhD, Howard Cabral, PhD, Tim Heeren, PhD, and Marjorie Beeghly, PhD, for their thoughtful comments. We also thank Ivana Hanson, BA, and Elizabeth Soares, BS, for their assistance in the preparation of the manuscript. We would particularly like to thank Lisa Blazejewski, MS, for her expert bibliographic and editorial assistance.





 
 
to Top
 

 

 
© 2001 American Medical Association. All rights reserved.
 

Hope you are enjoying your Tidbits. If you're not a member of ReconsiDer and would like to join please fill out our membership form.   And be sure to visit our website.


Click here to unsubscribe to this mailing list.